[1] GAO A,ZHANG L L,ZHONG D S.Chemotherapy-induced thrombocytopenia:literature review[J].Discov Oncol,2023,14(1):10. [2] GARRAUD O,HAMZEH-COGNASSE H,CHALAYER E,et al.Platelet transfusion in adults:an update[J].Transfus Clin Biol,2023,30(1):147-165. [3] WANG J,ZHOU P,HAN Y W,et al.Platelet transfusion for cancer secondary thrombocytopenia:platelet and cancer cell interaction[J].Transl Oncol,2021,14(4):101022. [4] SHI Q Y,JI T,TANG X D,et al.The role of tumor-platelet interplay and micro tumor thrombi during hematogenous tumor metastasis[J].Cell Oncol (Dordr),2023,46(3):521-532. [5] FALANGA A,RUSSO L,MILESI V,et al.Mechanisms and risk factors of thrombosis in cancer[J].Crit Rev Oncol Hematol,2017,118:79-83. [6] 符丹丽,陈培丰.恶性肿瘤高凝状态的中西医发病机制[J].肿瘤防治研究,2018,45(3):179-182. [7] 王伟军,程树群.实体瘤发生癌栓免疫逃避机制研究进展[J].中国实用外科杂志,2021,41(8):949-952. [8] ZHOU L,ZHANG Z,TIAN Y Z,et al.The critical role of platelet in cancer progression and metastasis[J].Eur J Med Res,2023,28(1):385. [9] YEUNG J,LI W J,HOLINSTAT M.Platelet signaling and disease:targeted therapy for thrombosis and other related diseases[J].Pharmacol Rev,2018,70(3):526-548. [10] TAO D L,TASSI YUNGA S,WILLIAMS C D,et al.Aspirin and antiplatelet treatments in cancer[J].Blood,2021,137(23):3201-3211. [11] HWANG B O,PARK S Y,CHO E S,et al.Platelet CLEC2-podoplanin axis as a promising target for oral cancer treatment[J].Front Immunol,2021,12:807600. [12] 陶倩倩,张雷,杜晓鹂,等.血小板介导的肿瘤微环境调控:活血化瘀中药的新靶点[J].中南药学,2021,19(6):1212-1218. [13] 田会茹,姜思琴,吕红,等.丹参注射液抑制血小板诱导的乳腺癌细胞体外转移作用[J].中国实验方剂学杂志,2023,29(21):79-85. [14] 孙立东. 鸡血藤提取物通过阻断“肿瘤-血小板” 互作抑制结肠癌转移的药效和机制研究[D].北京:中国中医科学院,2022. [15] 曹慧敏,吴瑾,贾连群,等.丹参酮ⅡA对心血管系统药理作用的研究进展[J].世界中医药,2017,12(7):1718-1722. [16] 黄刚,周世恒,罗贵全,等.丹参酮ⅡA磺酸钠注射液对急性心梗患者血小板活化功能的影响[J].中西医结合心血管病电子杂志,2017,5(3):21-22. [17] LIU H Y,LIU C Y,WANG M Y,et al.Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway[J].Sci Rep,2021,11(1):19268. [18] ZHOU M G,ZHOU G J,HU S H,et al.Tanshinone IIA suppress the proliferation of HNE-1 nasopharyngeal carcinoma an in vitro study[J].Saudi J Biol Sci,2018,25(2):267-272. [19] ZHOU L H,SUI H,WANG T,et al.Tanshinone IIA reduces secretion of pro-angiogenic factors and inhibits angiogenesis in human colorectal cancer[J].Oncol Rep,2020,43(4):1159-1168. [20] NIE Z Y,ZHAO M H,CHENG B Q,et al.Tanshinone IIA regulates human AML cell proliferation,cell cycle,and apoptosis through miR-497-5p/AKT3 axis[J].Cancer Cell Int,2020,20:379. [21] CHIU T L,SU C C.Tanshinone IIA increases protein expression levels of PERK,ATF6,IRE1α,CHOP,caspase-3 and caspase-12 in pancreatic cancer BxPC-3 cell-derived xenograft tumors[J].Mol Med Rep,2017,15(5):3259-3263. [22] SHIH C C,CHAN M V,KIRKBY N S,et al.Platelet inhibition by P2Y12 antagonists is potentiated by adenosine signalling activators[J].Br J Pharmacology,2021,178(23):4758-4771. [23] RIBES A,GARCIA C,GRATACAP M P,et al.Platelet P2Y1 receptor exhibits constitutive G protein signaling and β-arrestin 2 recruitment[J].BMC Biol,2023,21(1):14. [24] ZHANG H,PAN D A,WU X Q,et al.Platelet protease activated receptor 1 is involved in the hemostatic effect of 20(S)-protopanaxadiol by regulating calcium signaling[J].Front Pharmacol,2020,11:549150. [25] KÜNZE G,ISERMANN B.Targeting biased signaling by PAR1:function and molecular mechanism of parmodulins[J].Blood,2023,141(22):2675-2684. [26] HUANG J S,LI X,SHI X F,et al.Platelet integrin αIIbβ3:signal transduction,regulation,and its therapeutic targeting[J].J Hematol Oncol,2019,12(1):26. [27] LI H,JIANG W,ZHANG S R,et al.The platelet pannexin 1-IL-1β axis orchestrates pancreatic ductal adenocarcinoma invasion and metastasis[J].Oncogene,2023,42(18):1453-1465. [28] HASCHEMI R,GOCKEL L M,BENDAS G,et al.A combined activity of thrombin and P-selectin is essential for platelet activation by pancreatic cancer cells[J].Int J Mol Sci,2021,22(7):3323. [29] 胡谊容,田松明,赵福容.喉癌患者PAC-1、CD62P表达与临床病理特征和复发的关系[J].中国中西医结合耳鼻咽喉科杂志,2020,28(1):56-60. |